Literature DB >> 11454069

Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by preventing uptake of C567 onto cell membranes.

B A Fernie-King1, D J Seilly, C Willers, R Würzner, A Davies, P J Lachmann.   

Abstract

Streptococcal inhibitor of complement (SIC) was first described in 1996 as a putative inhibitor of the membrane attack complex of complement (MAC). SIC is a 31 000 MW protein secreted in large quantities by the virulent Streptococcus pyogenes strains M1 and M57, and is encoded by a gene which is extremely variable. In order to study further the interactions of SIC with the MAC, we have made a recombinant form of SIC (rSIC) in Escherichia coli and purified native M1 SIC which was used to raise a polyclonal antibody. SIC prevented reactive lysis of guinea pig erythrocytes by the MAC at a stage prior to C5b67 complexes binding to cell membranes, presumably by blocking the transiently expressed membrane insertion site on C7. The ability of SIC and clusterin (another putative fluid phase complement inhibitor) to inhibit complement lysis was compared, and found to be equally efficient. In parallel, by enzyme-linked immunosorbent assay both SIC and rSIC bound strongly to C5b67 and C5b678 complexes and to a lesser extent C5b-9, but only weakly to individual complement components. The implications of these data for virulence of SIC-positive streptococci are discussed, in light of the fact that Gram-positive organisms are already protected against complement lysis by the presence of their peptidoglycan cell walls. We speculate that MAC inhibition may not be the sole function of SIC.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11454069      PMCID: PMC1783247          DOI: 10.1046/j.1365-2567.2001.01249.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  22 in total

1.  Enhanced autoradiographic detection of 32P and 125I using intensifying screens and hypersensitized film.

Authors:  R A Laskey; A D Mills
Journal:  FEBS Lett       Date:  1977-10-15       Impact factor: 4.124

2.  The preparation and characterization of monoclonal antibodies to human complement component C8 and their use in purification of C8 and C8 subunits.

Authors:  A Abraha; B P Morgan; J P Luzio
Journal:  Biochem J       Date:  1988-04-01       Impact factor: 3.857

3.  Inhibition of alternative complement pathway opsonization by group A streptococcal M protein.

Authors:  P K Peterson; D Schmeling; P P Cleary; B J Wilkinson; Y Kim; P G Quie
Journal:  J Infect Dis       Date:  1979-05       Impact factor: 5.226

4.  Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H.

Authors:  R D Horstmann; H J Sievertsen; J Knobloch; V A Fischetti
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

5.  Immunoaffinity purification of human complement component C9 using monoclonal antibodies.

Authors:  B P Morgan; R A Daw; K Siddle; J P Luzio; A K Campbell
Journal:  J Immunol Methods       Date:  1983-11-25       Impact factor: 2.303

6.  Functionally active complement proteins C6 and C7 detected in C6- and C7-deficient individuals.

Authors:  R Würzner; A Orren; P Potter; B P Morgan; D Ponard; P Späth; M Brai; M Schulze; L Happe; O Götze
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

7.  Ig-binding surface proteins of Streptococcus pyogenes also bind human C4b-binding protein (C4BP), a regulatory component of the complement system.

Authors:  A Thern; L Stenberg; B Dahlbäck; G Lindahl
Journal:  J Immunol       Date:  1995-01-01       Impact factor: 5.422

8.  Regulation of complement functional efficiency by histidine-rich glycoprotein.

Authors:  N S Chang; R W Leu; J A Rummage; J K Anderson; J E Mole
Journal:  Blood       Date:  1992-06-01       Impact factor: 22.113

9.  Clusterin, the human apolipoprotein and complement inhibitor, binds to complement C7, C8 beta, and the b domain of C9.

Authors:  J Tschopp; A Chonn; S Hertig; L E French
Journal:  J Immunol       Date:  1993-08-15       Impact factor: 5.422

10.  Streptococcal C5a peptidase is a highly specific endopeptidase.

Authors:  P P Cleary; U Prahbu; J B Dale; D E Wexler; J Handley
Journal:  Infect Immun       Date:  1992-12       Impact factor: 3.441

View more
  37 in total

Review 1.  Subversion of the innate immune response by micro-organisms.

Authors:  B Fernie-King; D J Seilly; A Davies; P J Lachmann
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

2.  Genomic location and variation of the gene for CRS, a complement binding protein in the M57 strains of Streptococcus pyogenes.

Authors:  Michael Binks; David McMillan; Kadaba S Sriprakash
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

Review 3.  Complement and Bacterial Infections: From Molecular Mechanisms to Therapeutic Applications.

Authors:  Dani A C Heesterbeek; Mathieu L Angelier; Richard A Harrison; Suzan H M Rooijakkers
Journal:  J Innate Immun       Date:  2018-08-27       Impact factor: 7.349

4.  Streptococcus pneumoniae phosphoglycerate kinase is a novel complement inhibitor affecting the membrane attack complex formation.

Authors:  Anna M Blom; Simone Bergmann; Marcus Fulde; Kristian Riesbeck; Vaibhav Agarwal
Journal:  J Biol Chem       Date:  2014-10-03       Impact factor: 5.157

5.  Analysis of the transcriptome of group A Streptococcus in mouse soft tissue infection.

Authors:  Morag R Graham; Kimmo Virtaneva; Stephen F Porcella; Donald J Gardner; R Daniel Long; Diane M Welty; William T Barry; Claire A Johnson; Larye D Parkins; Fred A Wright; James M Musser
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

6.  Growth characteristics of and virulence factor production by group A Streptococcus during cultivation in human saliva.

Authors:  Samuel A Shelburne; Chanel Granville; Maria Tokuyama; Izabela Sitkiewicz; Payal Patel; James M Musser
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

7.  Insight into the molecular basis of pathogen abundance: group A Streptococcus inhibitor of complement inhibits bacterial adherence and internalization into human cells.

Authors:  Nancy P Hoe; Robin M Ireland; Frank R DeLeo; Brian B Gowen; David W Dorward; Jovanka M Voyich; Mengyao Liu; Eugene H Burns; Derek M Culnan; Anthony Bretscher; James M Musser
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

8.  Streptococcal inhibitor of complement promotes innate immune resistance phenotypes of invasive M1T1 group A Streptococcus.

Authors:  Morgan A Pence; Suzan H M Rooijakkers; Anna L Cogen; Jason N Cole; Andrew Hollands; Richard L Gallo; Victor Nizet
Journal:  J Innate Immun       Date:  2010-09-01       Impact factor: 7.349

9.  The interaction of streptococcal inhibitor of complement (SIC) and its proteolytic fragments with the human beta defensins.

Authors:  Barbara A Fernie-King; David J Seilly; Peter J Lachmann
Journal:  Immunology       Date:  2004-04       Impact factor: 7.397

Review 10.  Complement inhibition by gram-positive pathogens: molecular mechanisms and therapeutic implications.

Authors:  Alexander Laarman; Fin Milder; Jos van Strijp; Suzan Rooijakkers
Journal:  J Mol Med (Berl)       Date:  2010-02       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.